399 related articles for article (PubMed ID: 27055211)
1. Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study.
Donnenfeld ED; Karpecki PM; Majmudar PA; Nichols KK; Raychaudhuri A; Roy M; Semba CP
Cornea; 2016 Jun; 35(6):741-8. PubMed ID: 27055211
[TBL] [Abstract][Full Text] [Related]
2. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
[TBL] [Abstract][Full Text] [Related]
3. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease.
Nichols KK; Donnenfeld ED; Karpecki PM; Hovanesian JA; Raychaudhuri A; Shojaei A; Zhang S
Eur J Ophthalmol; 2019 Jul; 29(4):394-401. PubMed ID: 30112930
[TBL] [Abstract][Full Text] [Related]
5. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
[TBL] [Abstract][Full Text] [Related]
6. Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.
Keating GM
Drugs; 2017 Feb; 77(2):201-208. PubMed ID: 28058622
[TBL] [Abstract][Full Text] [Related]
7. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye.
Semba CP; Torkildsen GL; Lonsdale JD; McLaurin EB; Geffin JA; Mundorf TK; Kennedy KS; Ousler GW
Am J Ophthalmol; 2012 Jun; 153(6):1050-60.e1. PubMed ID: 22330307
[TBL] [Abstract][Full Text] [Related]
8. Lifitegrast for the treatment of dry eye disease in adults.
Donnenfeld ED; Perry HD; Nattis AS; Rosenberg ED
Expert Opin Pharmacother; 2017 Oct; 18(14):1517-1524. PubMed ID: 28841079
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease: A Post Hoc Analysis of 2 Randomized Clinical Trials.
Holland EJ; Jackson MA; Donnenfeld E; Piccolo R; Cohen A; Barabino S; Rolando M; Figueiredo FC
JAMA Ophthalmol; 2021 Nov; 139(11):1200-1208. PubMed ID: 34617974
[TBL] [Abstract][Full Text] [Related]
10. Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial.
Nichols KK; Holland E; Toyos MM; Peace JH; Majmudar P; Raychaudhuri A; Hamdani M; Roy M; Shojaei A
Clin Ophthalmol; 2018; 12():263-270. PubMed ID: 29440868
[TBL] [Abstract][Full Text] [Related]
11. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
Goldberg DF; Malhotra RP; Schechter BA; Justice A; Weiss SL; Sheppard JD
Ophthalmology; 2019 Sep; 126(9):1230-1237. PubMed ID: 30965064
[TBL] [Abstract][Full Text] [Related]
12. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.
Kinoshita S; Awamura S; Oshiden K; Nakamichi N; Suzuki H; Yokoi N;
Ophthalmology; 2012 Dec; 119(12):2471-8. PubMed ID: 23009892
[TBL] [Abstract][Full Text] [Related]
13. Safety and pharmacokinetics of a novel lymphocyte function-associated antigen-1 antagonist ophthalmic solution (SAR 1118) in healthy adults.
Semba CP; Swearingen D; Smith VL; Newman MS; O'Neill CA; Burnier JP; Haughey DB; Gadek TR
J Ocul Pharmacol Ther; 2011 Feb; 27(1):99-104. PubMed ID: 20334535
[TBL] [Abstract][Full Text] [Related]
14. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
[TBL] [Abstract][Full Text] [Related]
15. Lifitegrast (Xiidra) for dry eye disease.
Med Lett Drugs Ther; 2016 Aug; 58(1502):110-1. PubMed ID: 27552207
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial.
Matsumoto Y; Ohashi Y; Watanabe H; Tsubota K;
Ophthalmology; 2012 Oct; 119(10):1954-60. PubMed ID: 22739038
[TBL] [Abstract][Full Text] [Related]
17. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
Barber LD; Pflugfelder SC; Tauber J; Foulks GN
Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
[TBL] [Abstract][Full Text] [Related]
18. A 6-Week, Prospective, Randomized, Single-Masked Study of Lifitegrast Ophthalmic Solution 5% Versus Thermal Pulsation Procedure for Treatment of Inflammatory Meibomian Gland Dysfunction.
Tauber J
Cornea; 2020 Apr; 39(4):403-407. PubMed ID: 31895884
[TBL] [Abstract][Full Text] [Related]
19. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
Sall K; Stevenson OD; Mundorf TK; Reis BL
Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324
[TBL] [Abstract][Full Text] [Related]
20. Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease: Overview of Clinical Trial Program.
Chan CC; Prokopich CL
J Pharm Pharm Sci; 2019; 22(1):49-56. PubMed ID: 30636670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
